REFERENCES
- Vogelzang N. J., Rusthoven J. J., Symanowski J., Denham C., Kaukel E., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21(14)2636–2644, [PUBMED], [INFOTRIEVE], [CSA]
- Hanna N., Shepherd F. A., Fossella F. V., Pereira J. R., De Marinis F., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22(9)1589–1597, [INFOTRIEVE], [CROSSREF], [CSA]
- Martin M., Spielmann M., Namer M., duBois A., Unger C., et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann. Oncol. 2003; 14(8)1246–1252, [INFOTRIEVE], [CROSSREF], [CSA]
- John W., Picus J., Blanke C. D., Clark J. W., Schulman L. N., et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000; 88(8)1807–1813, [INFOTRIEVE], [CROSSREF], [CSA]
- Bajetta E., Celio L., Buzzoni R., Ferrari L., Marchiano A., et al. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann. Oncol. 2003; 14(10)1543–1548, [INFOTRIEVE], [CROSSREF], [CSA]
- Shih C., Chen V. J., Gossett L. S., Gates S. B., MacKellar W. C., et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997; 57(6)1116–1123, [INFOTRIEVE], [CSA]
- Zhao R., Babani S., Gao F., Liu L., Goldman I. D. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin. Cancer Res. 2000; 6(9)3687–3695, [INFOTRIEVE], [CSA]
- Mendelsohn L. G., Shih C. V., Chen J., Habeck L. L., Gates S. B., Shackelford K. A. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin. Oncol. 1999; 26(2 Suppl 6)42–47, [INFOTRIEVE], [CSA]
- Rinaldi D. A., Kuhn J. G., Burris H. A., Dorr F. A., Rodriguez G., et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 1999; 44(5)372–380, [CSA]
- Chaudhary A. K., Schannen V., Knadler M. P., Lantz R., Le Lacheur R. M. (1999) Analysis of LY231514 in plasma and urine using perchloric acid with LC/MS/MS. Proceedings of the 47th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, Texas, USA, June, 1999
- Shih C., Habeck L. L., Mendelsohn L. G., Chen V. J., Schultz R. M. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv. Enzyme Regul. 1998; 38: 135–152, [INFOTRIEVE], [CROSSREF], [CSA]
- McDonald A. C., Vasey P. A., Adams L., Walling J., Woodworth J. R., et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res. 1998; 4(3)605–610, [INFOTRIEVE], [CSA]
- Gandara D. R., Edelman M. J., Crowley J. J., Lau D. H., Livingston R. B. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother. Pharmacol. 1997; 41(1)75–78, [INFOTRIEVE], [CROSSREF], [CSA]
- Saland J. M., Leavey P. J., Bash R. O., Hansch E., Arbus G. S., Quigley R. Effective removal of methotrexate by high-flux hemodialysis Pediatr. Nephrol. 2002; 17(10)825–829, Epub 2002 Aug 9[CSA]
- Mohty M., Peyriere H., Guinet C., Hillaire-Buys D., Blayac J. P., Rossi J. F. Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure. Leuk. Lymphoma. 2000; 37(3–4)441–443, [INFOTRIEVE], [CSA]
- Krackhardt A., Schwartz S., Korfel A., Thiel E. Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure. Leuk. Lymphoma. 1999; 35(5–6)631–635, [INFOTRIEVE], [CSA]
- Widemann B. C., Balis F. M., Kempf-Bielack B., Bielack S., Pratt C. B., et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 2004; 100(10)2222–2232, [INFOTRIEVE], [CROSSREF], [CSA]
- Goldman I. D., Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin. Oncol. 2002; 29 6 Suppl 18: 3–17, [INFOTRIEVE], [CSA]
- Widemann B. C., Balis F. M., Murphy R. F., Sorensen J. M., Montello M. J., et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction J. Clin. Oncol. 1997; 15(5)2125–2134, [CSA]
- Castro M. Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure J. Clin. Oncol. 2003; 21(21)4066, [CROSSREF], [CSA]
- Curtin N. J., Hughes A. N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2001; 2(5)298–306, [INFOTRIEVE], [CROSSREF], [CSA]